• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Request Free Sample ×

    Kindly complete the form below to receive a free sample of this Report

    Leading companies partner with us for data-driven Insights

    clients tt-cursor

    Parkinsons Disease Therapeutics Market

    ID: MRFR/Pharma/1043-HCR
    90 Pages
    Rahul Gotadki
    September 2025

    Parkinson’s Disease Therapeutics Market Research Report Information By Treatment Type (Medication, Surgical Therapy, Carbidopa/Levodopa Enteral Suspension), By End-User (Hospitals & Clinics, Academic & Industrial Research), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) – Market Forecast Till 2032

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Parkinsons Disease Therapeutics Market Infographic
    Purchase Options
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Parkinsons Disease Therapeutics Market Summary

    The Global Parkinson's Disease Therapeutics Market is projected to grow significantly from 6.37 USD Billion in 2024 to 15.0 USD Billion by 2035.

    Key Market Trends & Highlights

    Parkinson’s Disease Therapeutics Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 8.07% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 15.0 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 6.37 USD Billion, reflecting the current demand for Parkinson's disease therapeutics.
    • Growing adoption of innovative treatment options due to increasing prevalence of Parkinson's disease is a major market driver.

    Market Size & Forecast

    2024 Market Size 6.37 (USD Billion)
    2035 Market Size 15.0 (USD Billion)
    CAGR (2025-2035) 8.07%

    Major Players

    GlaxoSmithKline Plc, Novartis AG, Orion Corporation, Salix Pharmaceuticals, Impax Laboratories LLC, Teva Pharmaceutical Industries Ltd, Mylan N.V., Par Pharmaceutical, Cipla Inc., Daiichi Sankyo

    Parkinsons Disease Therapeutics Market Trends

    Rising aging population coupled with increasing prevalence of Parkinson’s disease to boost market growth

    The aging population has been identified as a significant factor driving the market growth of Parkinson's Disease Therapeutics. Parkinson's Disease is a chronic and progressive neurological disorder that primarily affects older adults. As the global population ages, the prevalence of Parkinson's Disease is expected to increase, leading to a higher demand for therapeutics to manage the symptoms of the disease. Parkinson's Disease is more common among older adults, with the incidence of the disease increasing with age.

    As the population ages, the number of people diagnosed with Parkinson's Disease is expected to rise, leading to a higher demand for therapeutic options. There are currently 10 million Parkinson's patients living in the world. Elderly adults who have the condition face key clinical symptoms include slowness, stiffness, limb tremor, and postural instability among others as the disease advances. As a result, Parkinson's disease treatment concentrates on preserving the patient's level of activity and improving quality of life.

    Due to these characteristics, there is a significant need for treatments that are effective, which will drive up market revenue overall in the following years.

    Additionally, UN research estimates that 727 million people worldwide would be 65 years of age or older in 2020. In addition, it is anticipated that by 2050, there will be twice as many individuals worldwide who are 80 years of age or older. Because of this, major pharmaceutical companies have been able to significantly expand their market share in this industry. For pharmaceutical companies, the availability of various dosage forms can enable product diversification, resulting in higher profitability.

    According to the Parkinson’s Foundation more than 10 million people globally suffer from Parkinson Disease (PD), and 60,000 Americans have a diagnosis from Parkinson disease every year.

    Increasing drug approvals for the treatment of Parkinson's disease are anticipated to stimulate market expansion during the anticipated time frame. For instance, the Japanese pharmaceutical and biotechnology company Kyowa Kirin Co., Ltd. reported in August 2019 that the NOURIANZ medication has received FDA approval in the United States (istradefylline). It is used as an additional therapy to levodopa/carbidopa in adult patients with Parkinson's disease who are having 'OFF' episodes (PD).

    When a patient's medications are not functioning effectively, it can lead to an increase in Parkinson's disease (PD) symptoms like tremor and walking difficulties, which is known as a "off episode." In the US, NOURIANZ (istradefylline), an antagonist of the adenosine A2A receptor, is prescribed for Parkinson's disease. The medication offers patients with Parkinson's disease a brand-new non-dopaminergic once-daily oral therapeutic alternative.

    The ongoing advancements in neuroprotective therapies and the increasing focus on personalized medicine are reshaping the landscape of Parkinson’s Disease treatment, potentially enhancing patient outcomes and quality of life.

    National Institute of Neurological Disorders and Stroke (NINDS)

    Parkinsons Disease Therapeutics Market Drivers

    Market Growth Projections

    Advancements in Research and Development

    The Global Parkinson’s Disease Therapeutics Market Industry benefits from ongoing advancements in research and development. Innovative therapies, including gene therapy and neuroprotective agents, are emerging as potential game-changers in treatment paradigms. The increasing understanding of the disease's pathophysiology has led to the identification of novel therapeutic targets. As a result, pharmaceutical companies are investing heavily in clinical trials, which may lead to the introduction of new drugs in the market. This dynamic environment is likely to enhance the overall therapeutic landscape for Parkinson's disease, contributing to the projected CAGR of 8.07% from 2025 to 2035.

    Rising Awareness and Education Initiatives

    The Global Parkinson’s Disease Therapeutics Market Industry is also influenced by rising awareness and education initiatives aimed at both healthcare professionals and the general public. Increased understanding of Parkinson's disease symptoms and treatment options is crucial for early diagnosis and intervention. Organizations and advocacy groups are actively promoting educational campaigns, which may lead to higher rates of diagnosis and treatment adherence. This heightened awareness is likely to drive demand for therapeutics, as more individuals seek medical assistance upon recognizing symptoms. Consequently, the market is poised for growth as awareness translates into increased therapeutic utilization.

    Emerging Biologics and Personalized Medicine

    The emergence of biologics and personalized medicine represents a transformative shift within the Global Parkinson’s Disease Therapeutics Market Industry. These innovative approaches focus on tailoring treatments to individual patient profiles, enhancing efficacy and minimizing adverse effects. As research progresses, biologics targeting specific pathways involved in Parkinson's disease are being developed, offering new hope for patients. This trend aligns with the overall movement towards personalized healthcare, which is gaining traction globally. The introduction of such targeted therapies is likely to contribute to the market's expansion, as patients increasingly seek customized treatment options.

    Increasing Prevalence of Parkinson's Disease

    The Global Parkinson’s Disease Therapeutics Market Industry is experiencing growth driven by the rising prevalence of Parkinson's disease. As populations age, the incidence of this neurodegenerative disorder is expected to increase significantly. In 2024, the market is valued at approximately 6.37 USD Billion, reflecting the urgent need for effective therapeutic options. By 2035, the market is projected to reach 15.0 USD Billion, indicating a growing demand for innovative treatments. This trend suggests that healthcare systems worldwide must adapt to the increasing burden of Parkinson's disease, thereby fueling investment in research and development of new therapeutics.

    Growing Investment in Healthcare Infrastructure

    Investment in healthcare infrastructure is a crucial driver for the Global Parkinson’s Disease Therapeutics Market Industry. Governments and private entities are increasingly allocating resources to enhance healthcare facilities and improve access to treatment for patients with Parkinson's disease. This trend is particularly evident in developing nations, where healthcare systems are evolving to meet the needs of aging populations. Enhanced infrastructure facilitates better diagnosis, treatment, and management of the disease, ultimately leading to improved patient outcomes. As healthcare systems expand, the demand for effective therapeutics is expected to rise, further propelling market growth.

    Market Segment Insights

    Parkinson’s Disease Therapeutics Treatment Type Insights

    The Parkinson’s Disease Therapeutics Market segmentation, based on treatment Type, includes Medication, Surgical Therapy, and Carbidopa/Levodopa Enteral Suspension. The medication segment held the majority share in 2022 contribution to around ~65-67% in respect to the Parkinson’s Disease Therapeutics Market revenue. This is primarily owing to the rising prevalence of parkinson’s disease, rising research and development for the parkinson’s disease drug development that anticipated to support the market growth during forecast period.

    In November 2019, Biogen announced the initiation of a Phase 2 clinical trial of its experimental drug BIIB094, which is being developed as a treatment for Parkinson's Disease and other neurological disorders.

    In February 2020, Neurocrine Biosciences announced positive results from a Phase 2 clinical trial of its experimental drug NBI-827104, which is being developed as a treatment for Parkinson's Disease.

    Parkinson’s Disease Therapeutics End-User Insights

    The Parkinson’s Disease Therapeutics Market segmentation, based on end-user, includes Hospitals & Clinics, Academic & Industrial Research. The Hospitals & Clinics segment dominated the market in 2022 and is projected to be the faster-growing segment during the forecast period, 2024-2032. This is due to the rising prevalence of Parkinson's disease, the need for comprehensive care, advancements in treatment options, complex disease management, and access to specialized care is anticipated to support the market growth. Hence, rising demand in hospitals & clinics implants for parkinson’s disease therapeutics positively impacts the market growth.

    In May 2020, The Cleveland Clinic announced the launch of a new telemedicine program for Parkinson's Disease patients. The program enables patients to access remote consultations with Parkinson's Disease specialists, regardless of their location.

    In February 2021, The Penn Medicine Neuroscience Center in Philadelphia announced plans to launch a new Parkinson's Disease center, which will offer a range of clinical services and research programs.

    Figure 1: Parkinson’s Disease Therapeutics Market, by End User, 2022 & 2032 (USD Billion)

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Get more detailed insights about Parkinson’s Disease Therapeutics Market Research Report- Forecast to 2032

    Regional Insights

    By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. North America Parkinson’s Disease Therapeutics market accounted for USD 1.95 billion in 2022 and is expected to exhibit a significant CAGR growth during the study period. With a maximum sales share of 35%-39% in 2021, North America dominated the sector globally. Its dominance can be attributable to the presence of top competitors in the area, including Sunovion Pharmaceuticals Inc., Amneal Pharmaceuticals LLC, Merck & Co. Inc., and AbbVie Inc. By launching novel PD symptom treatment products, these players promote growth.

    For instance, Sunovion Pharmaceuticals Inc.'s Kynmobi was approved by the U.S. FDA in May 2020 to treat off-episodes in PD patients. Furthermore, it is projected that the region's extensive PD research will positively influence market expansion.

    Further, the major countries studied in the market report are: The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 2: PARKINSON’S DISEASE THERAPEUTICS MARKET SHARE BY REGION 2022 (%)PARKINSON’S DISEASE THERAPEUTICS MARKET SHARE BY REGION 2022

    Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

    Europe parkinson’s disease therapeutics market accounts for the second-largest market share due to the availability of cutting-edge treatment facilities, government backing for the growth of the healthcare industry, an ageing population, and an increase in prevenances of parkinson’s disease. Further, the Germany parkinson’s disease therapeutics market held the largest market share, and the UK parkinson’s disease therapeutics market was the fastest growing market in the European region

    The Asia-Pacific Parkinson’s Disease Therapeutics Market is expected to grow at the fastest CAGR from 2024 to 2032. This is due to rising number of generic medicine makers and the world's ageing population and rising investment in healthcare sector is anticipated to support the market’s growth is the region. Moreover, China parkinson’s disease therapeutics market held the largest market share, and the India parkinson’s disease therapeutics market was the fastest growing market in the Asia-Pacific region

    Key Players and Competitive Insights

    Major market players are spending a lot of money on R&D to increase their product lines, which will help the parkinson’s disease therapeutics market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, with key market developments such as new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the parkinson’s disease therapeutics industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

    One of the primary business strategies adopted by manufacturers in the global parkinson’s disease therapeutics industry to benefit clients and expand the market sector is to manufacture locally to reduce operating costs. In recent years, parkinson’s disease therapeutics industry has provided medicine and therapy with some of the most significant benefits. The parkinson’s disease therapeutics market major player such as GlaxoSmithKline Plc, Novartis AG, Orion Corporation and others are working to expand the market demand by investing in research and development activities.

    GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in London, UK. It was formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham. GSK is one of the largest pharmaceutical companies in the world, with operations in over 150 countries. GSK's main focus areas are pharmaceuticals, vaccines, and consumer healthcare. The company produces a range of prescription medicines, including treatments for respiratory diseases, cancer, and infectious diseases. GSK is also a leading producer of vaccines, with products targeting diseases such as influenza, meningitis, and shingles.

    In addition, the company produces consumer healthcare products, such as over-the-counter medicines, oral care products, and nutritional supplements. In May 2019, GSK announced a collaboration with the Michael J. Fox Foundation for Parkinson's Research to support the development of new therapeutic strategies for Parkinson's Disease.

    Novartis AG is a Swiss multinational pharmaceutical company headquartered in Basel, Switzerland. It was founded in 1996 through a merger of Ciba-Geigy and Sandoz, two large pharmaceutical companies with a long history of drug development and innovation. Novartis is one of the largest pharmaceutical companies in the world, with operations in more than 150 countries. The company has a diverse portfolio of products, including prescription medicines, generics, biosimilars, and over-the-counter products. Novartis' main focus areas include cardiovascular and metabolic diseases, oncology, neuroscience, and ophthalmology.

    In August 2019, Novartis AG announced positive results from a Phase 2 clinical trial of its experimental drug, ABBV-951. The drug is being developed in collaboration with AbbVie and is a treatment for advanced Parkinson's Disease.

    Key Companies in the Parkinsons Disease Therapeutics Market market include

    Industry Developments

    In June 2019, Biogen Inc. announced plans to acquire Nightstar Therapeutics, a gene therapy company focused on the development of treatments for inherited retinal diseases. Biogen's acquisition of Nightstar also included its Parkinson's Disease gene therapy program, which is in preclinical development.

    In October 2019, Adamas Pharmaceuticals launched a new product, Gocovri, for the treatment of dyskinesia in Parkinson's Disease patients who are on levodopa-based therapy. Gocovri is the first and only FDA-approved medication for this indication.

    In February 2020, Neurocrine Biosciences announced positive results from a phase 2 clinical trial of its Parkinson's Disease drug, NBI-827104. The drug showed significant improvement in motor function in patients with Parkinson's Disease, and the company plans to move forward with phase 3 trials.

    Future Outlook

    Parkinsons Disease Therapeutics Market Future Outlook

    The Global Parkinson’s Disease Therapeutics Market is projected to grow at 8.07% CAGR from 2024 to 2035, driven by advancements in drug development, increasing patient awareness, and enhanced healthcare infrastructure.

    New opportunities lie in:

    • Develop personalized medicine approaches to enhance treatment efficacy and patient adherence.
    • Invest in digital health technologies for remote monitoring and patient engagement.
    • Expand into emerging markets with tailored therapeutic solutions and localized strategies.

    By 2035, the market is expected to exhibit robust growth, reflecting advancements in therapeutics and increased global demand.

    Market Segmentation

    Parkinson’s Disease Therapeutics End-User Outlook

    • Hospitals & Clinics
    • Academic & Industrial Research

    Parkinson’s Disease Therapeutics Regional Outlook

    North America
    • US
    • Canada

    Parkinson’s Disease Therapeutics Treatment Type Outlook

    • Medication
    • Surgical Therapy
    • Carbidopa/Levodopa Enteral Suspension

    Report Scope

    Attribute/Metric Details
    Market Size 2023 USD 5.91 billion
    Market Size 2024 USD 6.37 billion
    Market Size 2032 USD 11.61 billion
    Compound Annual Growth Rate (CAGR) 8.80% (2024-2032)
    Base Year 2023
    Market Forecast Period 2024-2032
    Historical Data 2019 - 2022
    Market Forecast Units Value (USD Billion)
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Treatment Type, End-User and Region
    Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
    Countries Covered The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled Salix Pharmaceuticals, GlaxoSmithKline Plc, Impax Laboratories LLC, Teva Pharmaceutical Industries Ltd, Novartis AG, Orion Corporation, Mylan N.V., Par Pharmaceutical, Cipla Inc., Daiichi Sankyo
    Key Market Opportunities Strong Drug Pipeline
    Key Market Dynamics Growth in Aging Population and the Associated Increase in the Prevalence of Parkinson’s Disease Government Funding for Research

    Market Highlights

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    How much is the parkinson’s disease therapeutics market?

    The Parkinson’s Disease Therapeutics Market size was valued at USD 5.91 Billion in 2023.

    What is the growth rate of the parkinson’s disease therapeutics market?

    The global market is projected to grow at a CAGR of 8.80% during the forecast period, 2024-2032.

    Which region held the largest market share in the parkinson’s disease therapeutics market?

    North America had the largest share in the global market

    Who are the key players in the parkinson’s disease therapeutics market?

    The key players in the market are Salix Pharmaceuticals, GlaxoSmithKline Plc, Impax Laboratories LLC, Teva Pharmaceutical Industries Ltd, Novartis AG, Orion Corporation, Mylan N.V., Par Pharmaceutical, Cipla Inc., Daiichi Sankyo.

    Which Treatment Type led the parkinson’s disease therapeutics market?

    The Medication category dominated the market in 2022.

    Which End-User had the largest market share in the parkinson’s disease therapeutics market?

    The hospitals & clinics had the largest share in the global market.

    Parkinson’s Disease Therapeutics Market Research Report- Forecast to 2032 Infographic
    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Customer Stories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne Founder
    Case Study
    Chemicals and Materials